147 related articles for article (PubMed ID: 31834590)
1. Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?
Ménard T; Koneswarakantha B; Rolo D; Barmaz Y; Popko L; Bowling R
Drug Saf; 2020 Mar; 43(3):295-296. PubMed ID: 31834590
[No Abstract] [Full Text] [Related]
2. Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity.
Sartor O
Oncologist; 2018 Jan; 23(1):1. PubMed ID: 29158364
[TBL] [Abstract][Full Text] [Related]
3. SOP 08: Reporting of adverse events.
Onkologie; 2003 Oct; 26 Suppl 6():41-2. PubMed ID: 23570185
[No Abstract] [Full Text] [Related]
4. Under-reporting of harm in clinical trials.
Seruga B; Templeton AJ; Badillo FE; Ocana A; Amir E; Tannock IF
Lancet Oncol; 2016 May; 17(5):e209-19. PubMed ID: 27301048
[TBL] [Abstract][Full Text] [Related]
5. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
[TBL] [Abstract][Full Text] [Related]
6. Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning.
Ménard T; Barmaz Y; Koneswarakantha B; Bowling R; Popko L
Drug Saf; 2019 Sep; 42(9):1045-1053. PubMed ID: 31123940
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes and the evolution of adverse event reporting in oncology.
Trotti A; Colevas AD; Setser A; Basch E
J Clin Oncol; 2007 Nov; 25(32):5121-7. PubMed ID: 17991931
[TBL] [Abstract][Full Text] [Related]
8. Adverse event reporting in oncology clinical trials - lost in translation?
Sivendran S; Galsky MD
Expert Opin Drug Saf; 2016 Jul; 15(7):893-6. PubMed ID: 27070940
[No Abstract] [Full Text] [Related]
9. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.
Levit LA; Perez RP; Smith DC; Schilsky RL; Hayes DF; Vose JM
J Clin Oncol; 2018 Feb; 36(6):617-623. PubMed ID: 29236570
[No Abstract] [Full Text] [Related]
10. Supporting quality and patient safety in cancer clinical trials.
Badalucco S; Reed KK
Clin J Oncol Nurs; 2011 Jun; 15(3):263-5. PubMed ID: 21624861
[TBL] [Abstract][Full Text] [Related]
11. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection.
Tuccori M; Montagnani S; Capogrosso-Sansone A; Mantarro S; Antonioli L; Fornai M; Blandizzi C
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):61-75. PubMed ID: 25363790
[TBL] [Abstract][Full Text] [Related]
12. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
Maillet D; Gan HK; Blay JY; You B; Péron J
Eur J Cancer; 2016 Jan; 52():26-32. PubMed ID: 26630531
[TBL] [Abstract][Full Text] [Related]
13. Achieving the goals of effective, safe, and individualized cancer care.
Roberts SA; Karnes EK; Allen JD; Benner JS; Sigal EV; McClellan M
Clin Cancer Res; 2011 Nov; 17(21):6632-3. PubMed ID: 22046023
[No Abstract] [Full Text] [Related]
14. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
15. Assessing Drug Development Risk Using Big Data and Machine Learning.
Vergetis V; Skaltsas D; Gorgoulis VG; Tsirigos A
Cancer Res; 2021 Feb; 81(4):816-819. PubMed ID: 33355183
[TBL] [Abstract][Full Text] [Related]
16. Identification of discrepancies between adverse drug reactions coded by medical records technicians and those reported by the pharmacovigilance team in pediatrics: An intervention to improve identification, reporting, and coding.
Soyer J; Necsoiu D; Desjardins I; Lebel D; Bussières JF
Arch Pediatr; 2019 Oct; 26(7):400-406. PubMed ID: 31611146
[TBL] [Abstract][Full Text] [Related]
17. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
[TBL] [Abstract][Full Text] [Related]
18. Statistical methods for the analysis of adverse event data.
Kieser M
Pharm Stat; 2016 Jul; 15(4):290-1. PubMed ID: 27324410
[No Abstract] [Full Text] [Related]
19. Detecting adverse drug reactions in discharge summaries of electronic medical records using Readpeer.
Tang Y; Yang J; Ang PS; Dorajoo SR; Foo B; Soh S; Tan SH; Tham MY; Ye Q; Shek L; Sung C; Tung A
Int J Med Inform; 2019 Aug; 128():62-70. PubMed ID: 31160013
[TBL] [Abstract][Full Text] [Related]
20. Detection of drug safety signals from clinical trials data: Role of SUSARs.
Perez C; Olivier P; Lortal B; Duranton S; Montastruc JL; Colin AL; Toulza E; Becker M; Hamy L; Crepin S; Roussillon C; Gimbert A; Petitpain N; Salvo F
Pharmacol Res; 2018 May; 131():218-223. PubMed ID: 29444478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
